Khin Hnin Pwint1, Kyaw Soe Min2, Wenjing Tao3, Hemant Deepak Shewade4,5, Khin Thet Wai1, Hnin Aye Kyi2, Sushma Shakya6, Badri Thapa7, Rony Zachariah8, Zaw Than Htun1. 1. Department of Medical Research, Ministry of Health and Sports, Yangon 11191, Myanmar. 2. Department of Medical Services, Ministry of Health and Sports, Naypyidaw 15015, Myanmar. 3. Unit for Antibiotics and Infection Control, Public Health Agency of Sweden, 171 65 Stockholm, Sweden. 4. International Union Against TB and Lungs Disease (The Union), 75000 Paris, France. 5. The Union South East Asia, New Delhi 110001, India. 6. World Health Organization, Lalitpur 44700, Kathmandu, Nepal. 7. World Health Organization, 403 (A1), Bahan Township, Yangon 11201, Myanmar. 8. Special Program for Research and Training in Tropical Disease (TDR), 20 Avenue Appia, 1211 Geneva 27, Switzerland.
Abstract
(1) Background: In 2014, drug procurement for public hospitals in Myanmar was decentralized to a pull system. This might lead to increasing trends in the consumption of broad-spectrum and last-resort antibiotics. For fiscal years 2014-2017, we assessed annual antibiotic consumption trends and patterns in total defined daily doses (DDDs). (2) Methods: We followed World Health Organization (WHO) methodology for surveillance of antimicrobial consumption based on hospital antibiotic procurement records (as a proxy). (3) Results: In 32% of all public hospitals where data were retrieved, total antibiotic consumption reduced by 19% between 2014 (7,122,852 DDD) and 2017 (5,794,904 DDD). Consumption per 1000 inhabitants per day (<200 bed hospitals) also reduced from 0.6 to 0.3. Over 60% of procurement was for beta-lactam antibiotics and quinolones; quinolones decreased over time. Consumption of first-line antibiotics increased (42% in 2014 to 54% in 2017), whereas broad-spectrum antibiotics decreased (46% in 2014 to 38% in 2017). Linezolid was the only last-resort antibiotic procured. There was a progressive reduction in per capita government current health expenditure from approximately 9.2 US$ in 2014 to 8.3 US$ in 2017. (4) Conclusions: Antibiotic consumption decreased over time in public hospitals. This first study provides a baseline for developing an antibiotic consumption surveillance system in Myanmar.
(1) Background: In 2014, drug procurement for public hospitals in Myanmar was decentralized to a pull system. This might lead to increasing trends in the consumption of broad-spectrum and last-resort antibiotics. For fiscal years 2014-2017, we assessed annual antibiotic consumption trends and patterns in total defined daily doses (DDDs). (2) Methods: We followed World Health Organization (WHO) methodology for surveillance of antimicrobial consumption based on hospital antibiotic procurement records (as a proxy). (3) Results: In 32% of all public hospitals where data were retrieved, total antibiotic consumption reduced by 19% between 2014 (7,122,852 DDD) and 2017 (5,794,904 DDD). Consumption per 1000 inhabitants per day (<200 bed hospitals) also reduced from 0.6 to 0.3. Over 60% of procurement was for beta-lactam antibiotics and quinolones; quinolones decreased over time. Consumption of first-line antibiotics increased (42% in 2014 to 54% in 2017), whereas broad-spectrum antibiotics decreased (46% in 2014 to 38% in 2017). Linezolid was the only last-resort antibiotic procured. There was a progressive reduction in per capita government current health expenditure from approximately 9.2 US$ in 2014 to 8.3 US$ in 2017. (4) Conclusions: Antibiotic consumption decreased over time in public hospitals. This first study provides a baseline for developing an antibiotic consumption surveillance system in Myanmar.
Entities:
Keywords:
AWaRe; SORT IT; antibiotic stewardship; antimicrobial resistance; drug monitoring; health system resilience; operational research; surveillance
Authors: Erik von Elm; Douglas G Altman; Matthias Egger; Stuart J Pocock; Peter C Gøtzsche; Jan P Vandenbroucke Journal: Ann Intern Med Date: 2007-10-16 Impact factor: 25.391
Authors: Raphaël M Zellweger; Juan Carrique-Mas; Direk Limmathurotsakul; Nicholas P J Day; Guy E Thwaites; Stephen Baker Journal: J Antimicrob Chemother Date: 2017-11-01 Impact factor: 5.790